| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $8.1M | — | -32.3% |
| SG&A Expense | $11.4M | — | +81.5% |
| Operating Income | -$19.5M | — | -6.8% |
| Net Income | -$19.1M | — | -8.5% |
| EPS (Basic) | -$0.22 | — | +62.1% |
| EPS (Diluted) | -$0.22 | — | +62.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.8M | +179.6% | +750.3% |
| Short-term Investments | $224.2M | +150.5% | +765.2% |
| Current Assets | $235.3M | +150.4% | +750.9% |
| Total Assets | $235.4M | +150.4% | +750.3% |
| Current Liabilities | $12.9M | +100.5% | +146.4% |
| Total Liabilities | $16.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$15.1M | — | +16.6% |
| Investing Cash Flow | -$135.2M | — | -980.4% |
| Financing Cash Flow | $156.6M | — | — |
| +217.4% |
| Stockholders' Equity | $218.7M | +152.8% | +874.7% |